DARZALEX Faspro®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

DARZALEX®
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

Understanding Daratumumab Interference With Blood Compatibility Testing

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson

To Ensure Timely Transfusions

REMEMBER

For a patient who may receive DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) or DARZALEX® (daratumumab) and may require a transfusion:

- Type and screen patients prior to starting daratumumab and inform the blood bank that your patient has been treated with daratumumab
- Ensure that your patient's blood sample is identified as treated with daratumumab
- Double-check standing orders for transfusions to determine if your patient received daratumumab within the last year
- Provide your patient's pre-daratumumab compatibility profile, if available, to the blood bank
- Ask your patient to tell their other healthcare providers that they have received daratumumab, particularly before a transfusion

Daratumumab Results in a False Positive Indirect Coombs Test



- Daratumumab binds to CD38,[1] a protein that is expressed on red blood cells (RBCs)[2-4]
- Daratumumab binding to RBCs interferes with blood bank compatibility tests, including the antibody screening and crossmatching[1] (both indirect Coombs tests) that are part of a routine pretransfusion workup

Help Prevent Blood Transfusion Delays



- Blood compatibility testing can still be performed on daratumumab-treated patients
- Blood products for transfusion can be identified for daratumumab-treated patients using protocols available in the literature[1,5] or by using genotyping
- **To ensure that your patient receives a timely transfusion, type and screen patients prior to starting daratumumab and inform the blood bank that they will receive a daratumumab-treated sample**

Note: Additional information to share with your blood banks can be found in the Prescribing Information.

Daratumumab Interference Is Clinically Manageable

- Daratumumab does not interfere with identification of ABO/RhD antigens
- If an emergency transfusion is required, noncrossmatched, ABO/RhD-compatible RBCs can be given, per local blood bank practices[5]
- Once treatment with daratumumab is discontinued, panagglutination may persist; the duration of this effect varies from patient to patient, but may persist for up to 6 months after the last daratumumab infusion[5]

Additional Resources

For additional information, please contact Janssen Medical Information by using one of the following methods:

Phone: Call 1-800-JANSSEN (1-800-526-7736)

Email: Submit questions via our askjanssenmedinfo.com site

Search: www.janssenmd.com

Contact your local Medical Science Liaison: www.janssenmsl.com

References

1. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. *Transfusion.* 2015;55(6 Pt 2):1545-1554.
2. Albeniz I, Demir O, Türker-Sener L, Yalcintepe L, Nurten R, Bermek E. Erythrocyte CD38 as a prognostic marker in cancer. *Hematology*. 2007;12(5):409-414.
3. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. *FASEB J*. 1996;10(12):1408-1417.
4. Zocchi E, Franco L, Guida L, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. *Biochem Biophys Res Commun*. 1993;196(3):1459-1465.
5. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. *Transfusion*. 2015;55(6 Pt 2):1555-1562.

DARZALEX Faspro®
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

DARZALEX®
(daratumumab)
injection for intravenous infusion
100 mg/5 mL, 400 mg/20 mL

janssen | PHARMACEUTICAL COMPANIES OF Johnson & Johnson